ESC Premium Access

Angiotensin Receptor-Neprilysin Inhibitors (ARNi) should be first line instead of ACE-I in Class II-III Chronic Heart Failure - Pro.

Congress Presentation

About the speaker

Associate Professor David Sim

National Heart Centre Singapore, Singapore (Singapore)
7 presentations
0 follower

5 more presentations in this session

Angiotensin Receptor-Neprilysin Inhibitors (ARNi) should be first line instead of ACE-I in Class II-III Chronic Heart Failure- Contra.

Speaker: Professor J. Cleland (Glasgow, GB)

Thumbnail

Angiotensin Receptor-Neprilysin Inhibitors (ARNi) should be first line instead of ACE-I in Class II-III Chronic Heart Failure concluding discussion.

Thumbnail

PCI should be first choice in end stage renal failure patients with multivessel or LM disease - Pro.

Speaker: Professor M. Marwan (Erlangen, DE)

Thumbnail

PCI should be first choice in end stage renal failure patients with multivessel or LM disease - Contra

Speaker: Associate Professor K. Sin (Singapore, SG)

Thumbnail

PCI should be first choice in end stage renal failure patients with multivessel or LM disease - Concluding discussion.

Thumbnail

Access the full session

Controversies in 2019

Speakers: Associate Professor D. Sim, Professor J. Cleland, Professor M. Marwan, Associate Professor K. Sin
Thumbnail

About the event

Image

ESC Asia with APSC & AFC

8 November - 10 November 2019

Sessions Presentations

Related content

Open Access

Management of iron deficiency in heart failure - what do the guidelines say?

30 August 2021

Open Access

CRT, conduction system and alternative site pacing.

29 August 2021

ESC Premium Access

SGLT2 Inhibitors in heart failure.

29 August 2021

ESC 365 is supported by

logo Novo Nordisk